SEHK:2171
SEHK:2171Biotechs

CARsgen Therapeutics (SEHK:2171) Is Up 13.3% After Encouraging CAR-T Cell Therapy Results in Tough Cases

Earlier in November 2025, CARsgen Therapeutics Holdings announced updated clinical data for its allogeneic CAR-T cell therapy candidates, CT0596 and CT1190B, revealing initially favorable safety and efficacy outcomes in heavily pretreated patients with relapsed/refractory multiple myeloma and non-Hodgkin’s lymphoma. An interesting insight is that some patients who had failed multiple previous advanced therapies achieved complete responses, highlighting the potential impact of these...
SEHK:6618
SEHK:6618Consumer Retailing

JD Health International (SEHK:6618) Is Up 15.5% After Technology and Supply Chain Deals With JD.com - Has The Bull Case Changed?

JD Health International reported stronger-than-expected third quarter results, partnered with leading pharmaceutical companies, and announced agreements with JD.com involving technology support, supply chain solutions, and healthcare services, with these deals to be voted on at an upcoming general meeting. JD Health’s advances in digital healthcare and ongoing collaborations have reinforced its leadership in online specialty medicines and expanded the reach of its smart health ecosystem...
SEHK:2142
SEHK:2142Biotechs

A Look at HBM Holdings (SEHK:2142) Valuation Following AI-Focused Partnership With Evinova China

HBM Holdings (SEHK:2142) has announced a strategic partnership with Evinova China to leverage artificial intelligence and digital technologies in biologics research and development. This move is expected to add momentum to its innovation pipeline and market positioning. See our latest analysis for HBM Holdings. HBM Holdings’ latest surge, up 4% in a single day and 11.6% over the last week, follows the announcement of its AI-driven partnership with Evinova China. This signals that investors...
SEHK:2598
SEHK:2598Diversified Financial

Exploring Lianlian DigiTech (SEHK:2598) Valuation: Is the Market Overlooking Opportunity?

Lianlian DigiTech (SEHK:2598) has been catching some attention lately, with shares moving in various directions over the past week and month. Investors are weighing recent trading patterns in relation to the company’s overall financial trajectory. See our latest analysis for Lianlian DigiTech. Lianlian DigiTech’s share price has swung lower over the past quarter, with a 90-day share price return of -17.96% and a one-year total shareholder return of -13.4%. While momentum has faded recently,...
SEHK:1548
SEHK:1548Life Sciences

Why Genscript Biotech (SEHK:1548) Is Up 8.0% After Legend Biotech’s CARVYKTI Drives Smaller Q3 Loss

Earlier this week, Genscript Biotech Corporation announced that its associate, Legend Biotech Corporation, reported a significant reduction in net losses for the third quarter of 2025, alongside strong sales growth for its CARVYKTI product. This disclosure, released around Genscript’s Analyst/Investor Day, places enhanced focus on the financial ties between the two companies and the implications for Genscript’s broader business outlook. We’ll now explore how Legend Biotech’s improved...
SEHK:688
SEHK:688Real Estate

China Overseas Land (SEHK:688) Faces 55% Drop in Sales—What Does This Mean for Its Growth Story?

China Overseas Land & Investment Limited announced that in October 2025, contracted property sales fell to approximately RMB 18.66 billion, marking a 55.1% decrease year-on-year, with sales area down by 40%. This significant sales slowdown also contributed to a 21.3% year-on-year decline in accumulated contracted sales for the first ten months of 2025, highlighting pressure on the company's property development business. We will explore how the sharp drop in contracted sales shapes China...
SEHK:1797
SEHK:1797Consumer Retailing

East Buy Holding (SEHK:1797): Evaluating Valuation After Strategic Cash Deployment with Leading Chinese Banks

East Buy Holding (SEHK:1797) recently made headlines by subscribing to wealth management products from China Guangfa Bank and China Merchants Bank. This move highlights their strategic approach to managing surplus cash. See our latest analysis for East Buy Holding. Momentum has cooled for East Buy Holding, with a 1-month share price return of -12.62% and a steep 3-month decline. This comes even as investor interest in undervalued Asian stocks grows. Still, shareholders have seen a stellar...